QR Code

Tracking neuroinflammatory biomarkers in Alzheimer’s disease: a strategy for individualized therapeutic approaches?

Abstract Background Recent trials of anti-amyloid-β (Aβ) monoclonal antibodies, including lecanemab and donanemab, in early Alzheimer disease (AD) showed that these drugs have limited clinical benefits and their use comes with a significant risk of serious adverse events. Thus, it seems crucial to e...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Simone Lista, Bruno P. Imbimbo, Margherita Grasso, Annamaria Fidilio, Enzo Emanuele, Piercarlo Minoretti, Susana López-Ortiz, Juan Martín-Hernández, Audrey Gabelle, Giuseppe Caruso, Marco Malaguti, Daniela Melchiorri, Alejandro Santos-Lozano, Camillo Imbimbo, Michael T. Heneka, Filippo Caraci
Hōputu: Artigo
Reo:Inglês
I whakaputaina: BMC 2024-07-01
Rangatū:Journal of Neuroinflammation
Ngā marau:
Alzheimer’s disease
Neuroinflammation
Biomarkers
GFAP
YKL-40
ATI(N) classification system
Urunga tuihono:https://doi.org/10.1186/s12974-024-03163-y
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite